TB-500 for Cats: What Feline Research Actually Shows

TB-500 for Cats: The Short Answer

TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a peptide every mammal — cats included — produces naturally. Unlike dogs and horses, where at least some tissue-repair-adjacent animal research gets extrapolated to justify interest, the published, feline-specific literature on thymosin beta-4 is essentially limited to one data point: a proteomics study finding elevated Tβ4 in cats with hypertrophic cardiomyopathy. That's a disease-biomarker finding, not a treatment study, and it has nothing to do with the tissue-repair use case that drives most interest in TB-500. No feline intervention study — testing TB-500 as a treatment for anything in cats — appears to exist.

> Research disclaimer: This article reviews published animal and preclinical research for informational purposes only. It is not veterinary advice, and TB-500 is not an approved treatment for cats. Any decision about a cat's health should be made with a licensed veterinarian who can examine the animal. Nothing here should be read as a recommendation to administer any substance to an animal.

Why Cat Owners Encounter TB-500

Interest in TB-500 for cats generally comes secondhand — from the same wound-healing, tissue-repair, and anti-inflammatory research discussed for dogs in our canine research guide and for horses in our equine guide. Owners of senior cats dealing with arthritis, cats recovering from surgery, or cats with chronic wounds sometimes come across TB-500 discussed for those exact issues in humans or other species and reasonably wonder whether it applies to their cat too. The mechanistic story — angiogenesis, cell migration, anti-inflammatory signaling, reviewed in our mechanism of action guide — is generic mammalian biology in the sense that the same pathways exist in cats. Whether the peptide has been studied in cats, or whether dosing and safety data from other species transfers, are separate and much less settled questions.

The One Feline-Specific Data Point: A Cardiomyopathy Biomarker Study

Published feline research on thymosin beta-4 (referred to in this literature by its gene symbol, TMSB4X) comes from an entirely different direction than the injury-recovery framing that dominates interest in TB-500. A proteomics study of feline hypertrophic cardiomyopathy (HCM) — the most common heart disease in cats, notably prevalent in breeds like the Maine Coon and Bengal — found thymosin beta-4 elevated in the blood of symptomatic HCM cats compared to healthy controls, alongside other proteins involved in coagulation, such as serine protease inhibitors and antithrombin III.

This is worth being precise about: it's an expression-pattern finding in diseased tissue and blood, not a study of what happens when thymosin beta-4 or TB-500 is administered to a cat. Elevated levels of a protein in a disease state can reflect the disease process itself, a compensatory response the body mounts, or an incidental correlate — this study doesn't distinguish between those possibilities, and it says nothing about whether administering TB-500 would help, worsen, or have no effect on feline cardiomyopathy. It's mentioned here because it's the only cat-specific thymosin beta-4 finding in the published literature, not because it supports any therapeutic use.

What the Broader Animal Research Covers

Outside of that one feline biomarker study, thymosin beta-4 research relevant to cats comes entirely from other species: rodent models of wound healing and cardiac repair, equine tendon and ligament research covered in our horses guide, and the extrapolation-based canine interest covered in our dogs guide. None of that research was conducted in cats, and cross-species extrapolation is already a known limitation even between dogs and horses — species with more anatomical and injury-pattern similarity to each other than either has to cats.

Why Feline Physiology Adds Extra Caution

Cats are not simply small dogs, pharmacologically speaking. Feline metabolism has well-documented, clinically significant differences from other companion animals — most notably a reduced capacity for glucuronidation, a liver detoxification pathway that affects how cats process many common drugs and compounds differently than dogs or humans do. This is precisely why veterinary medicine treats drug and compound safety as something that has to be established species-by-species rather than assumed from related animals, and it's a specific reason to be skeptical of any extrapolation from dog, horse, or human TB-500 discussion directly onto cats. No feline-specific pharmacokinetic or safety data for thymosin beta-4 or TB-500 exists to confirm or rule out any species-specific concern.

What a Responsible Approach Looks Like

For a cat owner whose actual concern is their cat's health — arthritis, a slow-healing wound, post-surgical recovery — the evidence points toward a licensed veterinarian, not an unstudied research chemical. A veterinarian can diagnose the underlying condition and recommend treatments with an actual feline evidence base and appropriate dosing, which for most of these conditions already exist in veterinary medicine (NSAIDs formulated and dosed for cats, therapeutic diets, physical rehabilitation, and condition-specific feline protocols). TB-500 remains a research chemical without feline-specific safety, dosing, or efficacy data. The cardiomyopathy biomarker finding discussed above exists to accurately represent what the literature contains, not to suggest a use case.

What's Genuinely Unknown

Frequently Asked Questions

Has TB-500 been studied specifically in cats?

Only indirectly. The single cat-specific published finding is a proteomics study showing elevated thymosin beta-4 in cats with hypertrophic cardiomyopathy compared to healthy controls — an expression/biomarker finding, not a treatment study. No study has tested administering TB-500 to cats for any condition.

Is TB-500 safe for cats?

There's no established feline safety profile. Cats have documented, clinically significant metabolic differences from dogs and other species — including reduced capacity for a key liver detoxification pathway — which makes extrapolating safety data from other species particularly unreliable. Any decision about a cat's health should involve a licensed veterinarian.

Does the cardiomyopathy finding mean TB-500 could help or worsen feline heart disease?

The research doesn't answer that. It's an observation of elevated thymosin beta-4 in the blood of cats that already have hypertrophic cardiomyopathy, not a study of what happens when the peptide is administered. It doesn't establish causation, protective effect, or harm.

Why is the evidence for cats thinner than for dogs or horses?

Dogs and horses at least have indirect extrapolation available from rodent, equine-specific, and cardiac research applied to injury-recovery contexts, discussed in the respective guides for each species. Cats lack even that indirect injury-recovery research; the only cat-specific data point comes from an unrelated cardiomyopathy biomarker study.

What should I do if my cat has arthritis or a slow-healing wound?

Consult a licensed veterinarian who can examine and diagnose the specific condition. Feline-specific treatments with an established evidence base — properly dosed NSAIDs, therapeutic diets, wound management protocols, and physical rehabilitation — have a far stronger safety and efficacy record in cats than an unstudied research peptide.

Sourcing Quality Research Peptides

For laboratory research applications, compound identity and purity are essential — findings are only meaningful when the vial actually contains the labeled peptide at the stated purity. Apollo Peptide Sciences provides independent third-party testing and full COAs on its TB-500.

---

Related: TB-500 for Dogs Veterinary Research · TB-500 for Horses: Equine Guide · TB-500 Cardiac Research · TB-500 Side Effects and Safety